Search

Displaying results 2351 - 2360 of 10000 in total
  1. Drug

    Levocarnitine

    go.drugbank.com/drugs/DB00583
    ApprovedInvestigational

    It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.

    Synonyms: 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt
  2. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.

  3. Drug

    Cilnidipine

    go.drugbank.com/drugs/DB09232
    Investigational

    Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium … This drug is approved in China, Japan, Korea, India, and several countries in the European Union.[A31970]

  4. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.

  5. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … difficulties and commercial infeasibility in continuing drug distribution.

  6. Drug

    Clofazimine

    go.drugbank.com/drugs/DB00845
    ApprovedInvestigationalWithdrawn

    It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. … [A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis

  7. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.

  8. Drug

    Bovine type I collagen

    go.drugbank.com/drugs/DB10771
    ApprovedInvestigational

    It plays a vital role in cell growth, differentiation, attachment, and migration [L2481]. … Bovine collagen alpha-1 is a naturally occurring extracellular matrix protein which is found in tendons and other connective tissues.

  9. Drug

    Isoflurophate

    go.drugbank.com/drugs/DB00677
    ApprovedWithdrawn

    Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330) … An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma.

  10. Drug

    Moxifloxacin

    go.drugbank.com/drugs/DB00218
    ApprovedInvestigational

    Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

    Products: MOXIFLOXACINA DOUBLE-E PHARMA